Drug Profile
HB 201
Alternative Names: HB 200 programme; HB-201; TheraT® LCMVLatest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator Hookipa Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Head and neck cancer; Squamous cell cancer
- Phase I/II Cancer
- No development reported Cervical cancer
Most Recent Events
- 15 Apr 2024 Phase-II clinical trials in Head and neck cancer (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06373380)
- 15 Apr 2024 Phase-II clinical trials in Squamous cell cancer (Second-line therapy or greater, Chemotherapy-induced) in USA (IV) (NCT06373380)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Cervical-cancer(First-line therapy, Late-stage disease, Metastatic disease, Newly diagnosed) in USA (Intratumoural, Injection)